Rhenovia Pharma opens first US office
Aims to widen use of its biosimulation technology
Rhenovia Pharma, a French biotechnology company specialising in biosimulation applied to the discovery of drugs to treat brain diseases such as Alzheimer’s, has established its first international subsidiary in the US.
Rhenovia Inc will be based in the Greater Boston Area with offices in Cambridge, Massachusetts. It will focus on accelerating the search for new treatments for CNS diseases. It will do this through service partnerships in the form of studies using proprietary tools such as high throughput search for synergistic drug combinations, numerical pharmacological compound profiling, anticipation of safety/toxicity and drug-drug interaction risks, and alliances for the implementation of Rhenovia’s biosimulation in drug discovery and development.
Rhenovia will also be looking to expand its drug candidate pipeline as well as offering attractive investment opportunities.
Dr Serge Bischoff, president and ceo of Rhenovia Pharma, said: ‘It’s the right time to intensify our commercial activity and to move closer to our major pharma and biotech clients, and academic research partners.
‘It’s also time to disseminate worldwide the huge potential of Rhenovia’s technology of modelling and simulating neuronal transmission under normal and pathological conditions in the brain, the eye, the spinal cord and muscular junction.’
While biosimulation is routinely used in almost all non-CNS therapeutic fields, such as cardiovascular or infectious diseases, oncology, asthma, or HIV, it is still an emerging technology in mental, neurological, neurodegenerative and neurodevelopmental diseases.
‘However, this should not be a hurdle. On the contrary it will be a great opportunity to make the search for new medications more efficient, and more generally to provide answers to major societal and economic challenges, showing Rhenovia’s technology can be applied far beyond drug discovery,’ Bischoff added.
